Empagliflozin and the Risk of Retinopathy in Type 2 Diabetes

Дата публикации: 01-01-2025 00:00:00

This cohort study evaluates risk and progression of nonproliferative diabetic retinopathy in patients with type 2 diabetes with empagliflozin vs a dipeptidyl peptidase 4 inhibitor.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Event-Based Progression Detection Among OCT, OCTA, and VF in Glaucoma	0	9.28	03-09-2026
2	Widening the Spectrum of Disease Expression due to Heterozygous Variants in EFEMP1	0	14.91	10-09-2026
3	Artificial Intelligence for Diabetic Retinopathy	0	4.44	03-09-2026
4	Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease	0	3.79	03-09-2026
5	Highly Aspherical Lenslets for Myopia Control	0	6.82	20-08-2026
6	Support, Educate, Empower Program and Medication Adherence	0	4.95	01-04-2026
7	Ultra–Long-Distance Robotic-Assisted Subretinal Injection for Submacular Hemorrhage	0	16.79	20-08-2026
8	Digital Defocus Vision Training Using Virtual Reality for Myopia Control	0	9.14	27-08-2026
9	Time-Varying Effects of Valacyclovir Prophylaxis in the Zoster Eye Disease Study	0	8.29	01-09-2026
10	Dry Eye Disease Therapies at a Crossroads	0	6.4	17-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 11.22. Источник: jamanetwork.com.